Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, Beelen D, Socié G, Bornhäuser M, Angelucci E, Niederwieser D, Gerbitz A, Finke J, Vitek A, Itälä-Remes M, Radujkovic A, Kanz L, Potter V, Chevallier P, Stelljes M, Petersen E, Robinson S, Poiré X, Klyuchnikov E, Hernández-Boluda JC, Czerw T, Hayden P, Kröger N, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2019 Jul 5. pii: S1083-8791(19)30418-5. doi: 10.1016/j.bbmt.2019.06.034. [Epub ahead of print]

PMID:
31284069
2.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Jun 7. pii: S1083-8791(19)30362-3. doi: 10.1016/j.bbmt.2019.05.037. [Epub ahead of print]

PMID:
31181255
3.

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1450-1455. doi: 10.1016/j.bbmt.2019.03.003. Epub 2019 Mar 13.

PMID:
30876928
4.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016. Epub 2019 Jan 15. Review.

PMID:
30658222
5.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.

Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau IW, Ogawa S, Zemojtel T, Gerbitz A, Wagner EM, Spriewald BM, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F.

J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.

PMID:
30403573
6.

Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.

Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S, Zimmermann R, Zingsem J, Strobel J, Mackensen A, Mautner J, Moosmann A, Gerbitz A.

J Transl Med. 2018 May 9;16(1):124. doi: 10.1186/s12967-018-1498-3.

7.

IL-7 Abrogates the Immunosuppressive Function of Human Double-Negative T Cells by Activating Akt/mTOR Signaling.

Allgäuer A, Schreiner E, Ferrazzi F, Ekici AB, Gerbitz A, Mackensen A, Völkl S.

J Immunol. 2015 Oct 1;195(7):3139-48. doi: 10.4049/jimmunol.1501389. Epub 2015 Aug 31.

8.

Donor CD4 T Cell Diversity Determines Virus Reactivation in Patients After HLA-Matched Allogeneic Stem Cell Transplantation.

Ritter J, Seitz V, Balzer H, Gary R, Lenze D, Moi S, Pasemann S, Seegebarth A, Wurdack M, Hennig S, Gerbitz A, Hummel M.

Am J Transplant. 2015 Aug;15(8):2170-9. doi: 10.1111/ajt.13241. Epub 2015 Apr 14.

9.

Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma.

Bruns H, Büttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, Beier F, Pasemann S, Jitschin R, Hofmann AD, Neumann F, Daniel C, Maurberger A, Kempkes B, Amann K, Mackensen A, Gerbitz A.

Sci Transl Med. 2015 Apr 8;7(282):282ra47. doi: 10.1126/scitranslmed.aaa3230.

PMID:
25855493
10.

Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma.

Tudor CS, Bruns H, Daniel C, Distel LV, Hartmann A, Gerbitz A, Buettner MJ.

PLoS One. 2014 Dec 3;9(12):e114345. doi: 10.1371/journal.pone.0114345. eCollection 2014.

11.

Targeting high-grade B cell lymphoma with CD19-specific T cells.

Lehmann FM, Maurberger A, Feicht S, Helm F, Ladinig C, Kieback E, Uckert W, Kammertöns T, Kremmer E, Mautner J, Gerbitz A, Bornkamm GW.

Int J Cancer. 2014 Sep 1;135(5):1153-64. doi: 10.1002/ijc.28760. Epub 2014 Feb 20.

12.

Advances in cellular therapy: 7th international symposium on the clinical use of cellular products, March 14 and 15, 2013, Erlangen, Germany.

Aigner M, Bruns H, Gary R, Jitschin R, Kremer A, Mougiakakos D, Völkl S, Mackensen A, Gerbitz A.

Cancer Immunol Immunother. 2014 Feb;63(2):185-93. doi: 10.1007/s00262-013-1498-3. Epub 2013 Nov 5. No abstract available.

PMID:
24190547
13.

Targeting c-MYC with T-cells.

Helm F, Kammertoens T, Lehmann FM, Wilke A, Bruns H, Mautner J, Bornkamm GW, Gerbitz A.

PLoS One. 2013 Oct 10;8(10):e77375. doi: 10.1371/journal.pone.0077375. eCollection 2013.

14.

Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers.

Wolff D, Ayuk F, Elmaagacli A, Bertz H, Lawitschka A, Schleuning M, Meyer RG, Gerbitz A, Hilgendorf I, Hildebrandt GC, Edinger M, Klein S, Halter J, Mousset S, Holler E, Greinix HT.

Biol Blood Marrow Transplant. 2013 May;19(5):767-76. doi: 10.1016/j.bbmt.2013.01.018. Epub 2013 Jan 29.

15.

Humanized c-Myc mouse.

Lehmann FM, Feicht S, Helm F, Maurberger A, Ladinig C, Zimber-Strobl U, Kühn R, Mautner J, Gerbitz A, Bornkamm GW.

PLoS One. 2012;7(7):e42021. doi: 10.1371/journal.pone.0042021. Epub 2012 Jul 31.

16.

Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.

Mougiakakos D, Jitschin R, von Bahr L, Poschke I, Gary R, Sundberg B, Gerbitz A, Ljungman P, Le Blanc K.

Leukemia. 2013 Feb;27(2):377-88. doi: 10.1038/leu.2012.215. Epub 2012 Jul 25.

PMID:
22828446
17.

Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice.

Gerbitz A, Sukumar M, Helm F, Wilke A, Friese C, Fahrenwaldt C, Lehmann FM, Loddenkemper C, Kammertoens T, Mautner J, Schmitt CA, Blankenstein T, Bornkamm GW.

PLoS One. 2012;7(3):e34552. doi: 10.1371/journal.pone.0034552. Epub 2012 Mar 30.

18.

Advances in cellular therapy: 6th International Symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany.

Ullrich E, Bosch J, Aigner M, Voelkl S, Kroeger I, Hoffmann P, Kreutz M, Dudziak D, Gerbitz A.

Cancer Immunol Immunother. 2012 Mar;61(3):433-43. doi: 10.1007/s00262-011-1190-4. Epub 2011 Dec 27. No abstract available.

PMID:
22200930
19.

Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction.

Brunner S, Huber BC, Weinberger T, Vallaster M, Wollenweber T, Gerbitz A, Hacker M, Franz WM.

J Cell Mol Med. 2012 Jan;16(1):152-9. doi: 10.1111/j.1582-4934.2011.01286.x.

20.

Intrathecal application of donor lymphocytes in leukemic meningeosis after allogeneic stem cell transplantation.

Neumann M, Blau IW, Burmeister T, Tietze-Buerger C, Blau O, Gerbitz A, Uharek L, Thiel E.

Ann Hematol. 2011 Aug;90(8):911-6. doi: 10.1007/s00277-011-1171-x. Epub 2011 Feb 12.

PMID:
21318573
21.

Parathyroid hormone is a DPP-IV inhibitor and increases SDF-1-driven homing of CXCR4(+) stem cells into the ischaemic heart.

Huber BC, Brunner S, Segeth A, Nathan P, Fischer R, Zaruba MM, Vallaster M, Theiss HD, David R, Gerbitz A, Franz WM.

Cardiovasc Res. 2011 Jun 1;90(3):529-37. doi: 10.1093/cvr/cvr014. Epub 2011 Jan 18.

PMID:
21245057
22.

CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells.

Dürr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, Krüger S, Gerbitz A, Negrin RS, Finke J, Zeiser R.

Cancer Res. 2010 Dec 15;70(24):10170-81. doi: 10.1158/0008-5472.CAN-10-1943.

23.

Identification of MHC II-restricted minor histocompatibility antigens after HLA-identical stem-cell transplantation.

Milosevic S, Bachnick B, Karim K, Bornkamm GW, Witter K, Gerbitz A, Mautner J, Behrends U.

Transplantation. 2010 Nov 15;90(9):1030-5. doi: 10.1097/TP.0b013e3181f5470c.

PMID:
20802400
24.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.

Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic SZ, Greinix H, Holler E.

Biol Blood Marrow Transplant. 2011 Jan;17(1):1-17. doi: 10.1016/j.bbmt.2010.05.011. Epub 2010 May 26.

25.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.

Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1611-28. doi: 10.1016/j.bbmt.2010.06.015. Epub 2010 Jun 25.

26.

Influence of polymorphism within the heme oxygenase-I promoter on overall survival and transplantation-related mortality after allogeneic stem cell transplantation.

Gerbitz A, Hillemanns P, Schmid C, Wilke A, Jayaraman R, Kolb HJ, Eissner G, Holler E.

Biol Blood Marrow Transplant. 2008 Oct;14(10):1180-1189. doi: 10.1016/j.bbmt.2008.08.002.

27.

High serum concentrations of cyclosporin related to administration of tigecycline.

Stumpf AN, Schmidt C, Hiddemann W, Gerbitz A.

Eur J Clin Pharmacol. 2009 Jan;65(1):101-3. doi: 10.1007/s00228-008-0557-8. Epub 2008 Sep 16. No abstract available.

PMID:
18795273
28.

G-CSF treatment after myocardial infarction: impact on bone marrow-derived vs cardiac progenitor cells.

Brunner S, Huber BC, Fischer R, Groebner M, Hacker M, David R, Zaruba MM, Vallaster M, Rischpler C, Wilke A, Gerbitz A, Franz WM.

Exp Hematol. 2008 Jun;36(6):695-702. doi: 10.1016/j.exphem.2008.01.011. Epub 2008 Mar 17.

PMID:
18346841
29.

High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.

Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb HJ.

Bone Marrow Transplant. 2008 Apr;41(8):721-7. doi: 10.1038/sj.bmt.1705965. Epub 2008 Jan 7.

PMID:
18176613
30.
31.

Expression of heme oxygenase-1 protects endothelial cells from irradiation-induced apoptosis.

Ewing P, Wilke A, Eissner G, Holler E, Andreesen R, Gerbitz A.

Endothelium. 2005 May-Jun;12(3):113-9.

PMID:
16291514
32.

Recovery from CMV esophagitis after allogeneic bone marrow transplantation using non-myeloablative conditioning: the role of immunosuppression.

Fiegl M, Gerbitz A, Gaeta A, Campe H, Jaeger G, Kolb HJ.

J Clin Virol. 2005 Nov;34(3):219-23. Epub 2005 Aug 29.

PMID:
16129661
33.

A role for CD54 (intercellular adhesion molecule-1) in leukocyte recruitment to the lung during the development of experimental idiopathic pneumonia syndrome.

Gerbitz A, Ewing P, Olkiewicz K, Willmarth NE, Williams D, Hildebrandt G, Wilke A, Liu C, Eissner G, Andreesen R, Holler E, Guo R, Ward PA, Cooke KR.

Transplantation. 2005 Mar 15;79(5):536-42.

PMID:
15753842
34.

A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome.

Gerbitz A, Nickoloff BJ, Olkiewicz K, Willmarth NE, Hildebrandt G, Liu C, Kobzik L, Eissner G, Holler E, Ferrara JL, Cooke KR.

Transplantation. 2004 Aug 27;78(4):494-502.

PMID:
15446306
35.

Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Gerbitz A, Ewing P, Wilke A, Schubert T, Eissner G, Dietl B, Andreesen R, Cooke KR, Holler E.

Biol Blood Marrow Transplant. 2004 Jul;10(7):461-72.

36.

Cerebral endothelial expression of adhesion molecules in mice with chronic graft-versus-host disease.

Sostak P, Reich P, Padovan CS, Gerbitz A, Holler E, Straube A.

Stroke. 2004 May;35(5):1158-63. Epub 2004 Apr 8.

PMID:
15073401
37.

Probiotic effects on experimental graft-versus-host disease: let them eat yogurt.

Gerbitz A, Schultz M, Wilke A, Linde HJ, Schölmerich J, Andreesen R, Holler E.

Blood. 2004 Jun 1;103(11):4365-7. Epub 2004 Feb 12.

38.

Isolation and transplantation of allogeneic pulmonary endothelium derived from GFP transgenic mice.

Ewing P, Wilke A, Brockhoff G, Andreesen R, Eissner G, Holler E, Gerbitz A.

J Immunol Methods. 2003 Dec;283(1-2):307-15.

PMID:
14659921
39.

Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide.

Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S, Sondermann D, Andreesen R, Holler E.

Blood. 2002 Jul 1;100(1):334-40.

40.

LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL.

J Clin Invest. 2001 Jun;107(12):1581-9.

41.

Cerebral involvement in graft-versus-host disease after murine bone marrow transplantation.

Padovan CS, Gerbitz A, Sostak P, Holler E, Ferrara JL, Bise K, Straube A.

Neurology. 2001 Apr 24;56(8):1106-8.

PMID:
11320189
42.
43.

Burkitt lymphoma in the mouse.

Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC 3rd.

J Exp Med. 2000 Oct 16;192(8):1183-90.

44.

Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation.

Cooke KR, Hill GR, Gerbitz A, Kobzik L, Martin TR, Crawford JM, Brewer JP, Ferrara JL.

Transplantation. 2000 Jul 27;70(2):272-9.

PMID:
10933148
45.

G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient.

Reddy V, Hill GR, Pan L, Gerbitz A, Teshima T, Brinson Y, Ferrara JL.

Transplantation. 2000 Feb 27;69(4):691-3.

PMID:
10708136
46.

Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Hill GR, Teshima T, Gerbitz A, Pan L, Cooke KR, Brinson YS, Crawford JM, Ferrara JL.

J Clin Invest. 1999 Aug;104(4):459-67.

47.

Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma.

Gerbitz A, Mautner J, Geltinger C, Hörtnagel K, Christoph B, Asenbauer H, Klobeck G, Polack A, Bornkamm GW.

Oncogene. 1999 Mar 4;18(9):1745-53.

48.

Supplemental Content

Loading ...
Support Center